CPSA Europe 2020

Meeting Programme

Updated 10 December, 2019

Tuesday | Wednesday | Thursday | Friday

Tuesday February 4

12:00 pm

Lobby

Registration

Front Lobby

1:00 pm - 4:30 pm

Pre-Conference Workshops

Queen's Room

WORKSHOP 1
The Future of Personalised Healthcare:
Integrated Solutions

Workshop Leader: Emily Ehrenfeld, New Objective

Magdalene Room

WORKSHOP 2
To Be Announced

6:00 PM - 9:00 pm

College Suite

Welcome Reception & IMAGINE SUMMIT

Imagine Summit
Building Tomorrow Today

Welcome
Neil Spooner, Spooner Bioanalytical Solutions and
Emily Ehrenfeld, New Objective

Christophe Stove

Imagineer
Christophe Stove
University of Ghent

Wednesday February 5

7:00 AM - 8:30 AM

Lobby

Registration

Front Lobby

8:30 AM - 8:45 AM

University Suite

Welcome & Opening Remarks

Mike Lee

Welcome
Mike Lee
Milestone Development Services

Neil Spooner

Format, Objectives, Opening Remarks
Neil Spooner
Spooner Bioanalytical Solutions

Ismael Zamora


Ismael Zamora
Molecular Discovery

8:45 am - 9:30 am

University Suite

Plenary Lecture

Duchenne Muscular Dystrophy – Why the Way We Sample Blood Matters
"Mum - why don’t they just punch me in the face?"

Fleur Chandler

Fleur Chandler

Duchenne UK

9:45 am - 11:30 am

University Suite

Session 1
Symposium Session

Pushing the Boundaries of Sample Collection – Near and Small

Discussion Leaders: Emily Ehrenfeld, New Objective; Matt Barfield, GlaxoSmithKline

With such an impactful plenary speaker we didn’t want to jump straight into a series of presentation, so this session is a panel discussion bringing together leading experts with the vision and passion to challenge the status quo. The theme is based on delivering the promise of near patient sampling, overcoming the perceived and real obstacles but most importantly listening and learning from the patient. This session is designed to focus on the patient and sets the theme that will run throughout the meeting and aims to deliver the dream

Panelists:
James Rudge, Neoteryx
Christophe Stove, University of Ghent
Erwin Berthier, Tasso, Inc.
Deanne Rudd, MSD (Merck & Co. USA/Canada)
Scott Summerfield, GlaxoSmithKline
Jenny Royle, digital Experimental Cancer Medicine Team
Fleur Chandler, Duchenne UK

11:30 am - 1:00 pm

Parallel Sessions

University Suite

Session 2
To Be Announced

Discussion Leaders: Deanne Rudd, MSD (Merck & Co. USA/Canada); Ian Dawson, Covance

Corpus Christi Room

Session 3
Getting the ‘i’ into Clinical Trials
(To Improve Patient Outcomes and Data Integrity)

Discussion Leaders: Jenny Royle, digital Experimental Cancer Medicine Team; Scott Summerfield, GlaxoSmithKline

Creativity and progress is frequently hampered by people not collaborating across boundaries. This session uses the World Café format to structure a fun and interactive discussion on how to break down these boundaries and speed up deployment of new innovations in trials.

The aim is to focus on problems you have. So, to win the chance of getting the whole conference helping to solve your issue, send your topic now to Jenny Royle for it to be added into the hat.

Hang your coats at the door, roll up your sleeves, and let’s begin…

1:15 pm - 2:45 pm

College Suite

Sponsored Lunch & Roundtable

The Future of Personalised Healthcare:
Integrated Solutions – Mapping a Path Forward for Microsampling and Separations

Discussion Leaders: Matt Barfield, GlaxoSmithKline; Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development; Emily Ehrenfeld, New Objective

2:45 pm - 4:15 pm

University Suite

Workshop

To Be Announced

Discussion Leaders: Britta Bonn, AstraZeneca; Ute Gerhard, University of Hertfordshire; Emre Isin, UCB; Darragh Murnane, University of Hertfordshire

4:30 pm - 6:00 pm

Parallel Sessions

University Room

SESSION 4
To Be Announced

Discussion Leaders: Amanda Wilson, AstraZeneca; Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

Corpus Christi Room

SESSION 5
Imaging Technologies for Applied Clinical Research

Discussion Leaders: David Browne, PRA Health Sciences;  Michelle Reid, ETH Zurich

During this session, the speakers will highlight imaging techniques for patient diagnosis and treatment improvements.

Mass Spectrometry in Medicine
Michael Morris, Waters Corporation

This talk will look at the potential of mass spectrometry (MS) for the support of tissue identification in real-time using direction ionization techniques. With greater acceptance of MS technology, other avenues have opened for the use of MS in routine medical science, including imaging and automated analysis.

Morphological Detection of Cancer Cells by Deep Learning Improves Personalized Drug Testing
Tim Heinemann, ETH Zurich

We trained multiple network architectures to classify cancer cells from label-free imaging channels, either per patient or across all patients, and benchmarked their performance against cancer cell detection by immunofluorescence (IF) against diagnostic markers. Remarkably, treatments recommended by a single convolutional neural network (CNN) trained across all patients clinically outperformed those recommended by IF and all other networks. Through single CNN and IF recommended treatments, image-based drug response can be improved in patient biopsies for personalized medicine.

6:00 pm

University Suite

CPSA EUROPE GROUP PHOTO

Please gather toegther to capture the 3rd Annual CPSA Europe gathering with a group photo—including organizers, speakers, attendees—everyone!

6:30 pm - 8:30 pm

College Suite

Sponsored Reception & Dinner

Thursday February 6

7:00 AM - 8:30 AM

Lobby

Registration

Front Lobby

8:30 am - 10:00 am

University Suite

Session 1
Symposium Session

Emerging Technologies to Enable a Paradigm Shift from "Sick Care" to "Health Care"

Discussion Leaders: Pawanbir Singh, Trajan Scientific and Medical; Emre Isin, UCB

The primary goal for pharmaceutical industry is to develop medicines with the right exposure, reach the right target and treat the right patient. However, in the present information rich world, the ultimate objective is not only to control symptoms and treat disease but provision of technologies that facilitate both disease prevention and disease management. The enormity of this objective requires a transformative change. On one hand, there is the need to develop and have access to novel technologies which accelerate the drug development process and on the other, novel tools that enable a prevention model by focusing on forestalling disease development before clinical manifestation.

The objective of this session is to discuss emerging technologies and avenues to facilitate a paradigm shift from "sick care” to “health care"

Patterns of health and disease: Molecular images in cellular context
Ron Heeren, M4I, Maastricht University

To Be Announced
Muireann Coen, Imperial College London and AstraZeneca

10:15 am - 11:45 am

The University Suite

Session 2
Symposium Session

What can the bioanalytical community learn from other analytical based industries and workflows?

Discussion Leaders: Elizabeth Thomas, Alderley Analytical; Nathan Hawkins, Anatune; Jason Wrigley, Merck (MilliporeSigma in USA/Canada); Neil Spooner, Spooner Bioanalytical Solutions

To Be Announec
Dominic Harrington Kings College, London & Viapath

12:00 pm - 1:30 pm

College Suite

Sponsored Lunch & Roundtable

1:30 pm - 3:00 pm

University Suite

WORKSHOP 1
WORKSHOP

Are Current Clinical Chemistry Tests Still Fit for Purpose?

Discussion Leaders: Amanda Wilson, AstraZeneca;
James Rudge, Neoteryx

To Be Announced
Brian Keevil, Manchester University NHS Foundation Trust

3:15 pm - 4:45 pm

Parallel Sessions

University Suite

SESSION 3
The Bedside Bioanalyst

Discussion Leaders: Ian Wilson, Imperial College (London); John Smeraglia, UCB

Bringing high quality analytical chemistry to the patient in the operating theatre, at their bedside, in the GP's surgery, or their own homes for therapeutic drug monitoring, biomarker analysis, diagnosis and therapy monitoring.

If we have learned nothing from the Theranos scandal its that there is both a need, and an appetite, from individuals for good, accurate and reliable analytical information about health, disease the causes and time-course of disease, and the outcome of therapies.

How can we deliver it?

Corpus Christi Room

SESSION 4
Social Media and Scientific Publishing in the 21st Century

Discussion Leaders: Laura Dormer, Future Science Group; Shane Needham, Alturas Analytics

There are already many new ways to share information beyond the traditional printed white paper/research article. This session will include discussion between the panel members and audience on how they currently share their information and data, how this might evolve in the future utilizing electronic platforms and social media, and what risks/challenges/opportunities this might present.

Discussion Panelists:
Jenny Royle, digital Experimental Cancer Medicine Team
Michell Reid, ETH Zurich
Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

5:00 pm - 6:30 pm

The University Suite

Vendor Session

"Five Minutes of Fame"

Discussion Leaders: Elizabeth Thomas, Alderley Analytical; Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development Services

Participants are given the opportunity to present their idea, company, products and services to the participants of CPSA Europe 2020 using any format they'd like. The only rule is it is limited to just 5 minutes! Be bold, have fun, get noticed and make a statement.

6:30 pm - 8:30 pm

College Suite

Sponsored Evening Event & Dinner

The Future of Personalised Healthcare: Integrated Solutions – Mapping a Path Forward for Sample Preparation and Data

Discussion Leaders: Matt Barfield, GlaxoSmithKline; Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development; Emily Ehrenfeld, New Objective

Friday February 7

7:00 AM - 8:30 AM

Lobby

Registration

Front Lobby

8:30 am - 10:15 am

Peterhouse Room

Session 1
Symposium Session

The Future of Digital Biomarkers

Discussion Leaders: Kevin Bateman, MSD (Merck & Co. in USA/Canada; James Rudge, Neoteryx; Jenny Royle, digital Experimental Cancer Medicine Team

The Potential of Digital Biomarkers to Transform Drug Development
Marissa Dockendorf, MSD (Merck & Co. in USA/Canada)

Can Remote Blood Testing and Digital Biomarkers Drive Behavioural Change?
Bala Sirigireddy, NHS Clinical Entrepreneur Fellow

Digital Biomarkers – What’s the Point?
Early Clinical Trial Experience
Jenny Royle, digital Experimental Cancer Medicine Team

10:15 am - 12:00 pm

Peterhouse Room

Session 2
Symposium Session

Little by Little:
Mixing Microfluidics and Clinical Microsamples

Discussion Leaders: Christophe Stove, Ghent University; Ute Gerhard, University of Hertfordshire; Darragh Murnane, University of Hertfordshire; Dan Baker, University of Hertfordshire

Developments in silicon nanotechnology for healthcare applications
Tim Stakenborg, IMEC

Diagnostics where you need it
Jan-Willem Hoste, Antelope DX

12:00 pm - 1:30 pm

Peterhouse Room

Lunch & Symposium Session

How Does Software Impact Your Scientific Life? It’s Getting Personal!

Discussion Leaders: Ismael Zamora, Molecular Discovery

The capabilities of scientific software, such as those used for metabolite identification, are becoming increasingly sophisticated. This is now coming to the point where these solutions are able to fulfil many of the functions currently performed by skilled scientists, which brings us to an interesting junction….. This discussion based sessions will encourage attendees to reflect on where we might be goings with regards to these solutions. What might be the benefits and risks of their implementation and how should we be moving forwards to enable us to develop better solutions for human wellbeing and the patients that are waiting for better diagnoses and medicines.

1:30 pm

Peterhouse Room

Closing Remarks

Neil Spooner, Spooner Bioanalytical Solutions
Ismael Zamora, Molecular Discovery
Mike Lee, Milestone Development Services